Summary Whether duodenal adenocarcinoma should be considered as a gastrointestinal or as a peripancreatic cancer is a matter of debate, as is the opportunity and type of treatment. We investigated 12 such cancers for the genetic anomalies involved in the pathogenesis of gastrointestinal malignancies, including (a) those occurring in common-type cancers -allelic losses at chromosomes 3p, 5q, 1 7p and 1 8q, and Ki-ras and p53 alterations; and (b) those characteristic of mutator-phenotype cancers -microsatellite instability and TGF-PRII gene mutations. We found Ki-ras and p53 mutations in five (42%) and eight cancers (67%), respectively; chromosome 3p, 5q, 1 7p and 1 8q allelic losses in two of nine (22%), six of ten (60%), six of nine (67%) and three of ten (30%) informative cancers, respectively. Finally, three cancers (25%) showed widespread microsatellite instability and two of them had a TGF-pRII gene mutation. Our data suggest that duodenal cancers may arise from either of the two known pathogenetic molecular pathways of gastric and colorectal cancers. The majority of our cases were highly aggressive cancers with frequent chromosomal changes and p53 mutations as observed in the common-type gastrointestinal malignancies, while widespread subtle alterations characteristic of mutator-phenotype cancers occurred in a minority, which also showed a favourable long-term outcome.
Sporadic cancer of the duodenum not originating from the ampulla of Vater is a very rare disease. Yet it is the most common adenocarcinoma of the small intestine and kills 70% of affected patients, with a median survival of 20 months from diagnosis (Rose et al, 1996; Sexe et al, 1996) . The natural history and outcome of this disease are poorly defined, because of its rarity and the inclusion of the few cases described in the literature within the category of periampullary cancers. The decision as to whether a duodenal adenocarcinoma should be viewed as a gastrointestinal cancer or as a peripancreatic cancer, with which the presentation is usually confused, is unclear (Brennan, 1990; Klempnauer et al, 1995; Rose et al, 1996) . This is not a trivial question, as it also involves controversy on the opportunity and type of surgical and/or chemotherapeutic treatment (Brennan, 1990; Klempnauer et al, 1995; Rose et al, 1996) . The study of duodenal cancers may also help to unravel the molecular pathogenesis of cancers arising in the periampullary area, including cancers of the papilla of Vater, of the biliary tract and of the pancreatic head.
Two molecular pathways are known to lead to gastric and colorectal cancer, termed the 'tumour suppressor' and the 'mutator' pathways (Perucho, 1996; Shibata, 1996) . To the first belong the more common sporadic cancers, in which the pacemakers of tumour genesis and progression are the gross chromosomal changes and discrete mutations leading to the alteration of oncogenes and tumour suppressor genes, involved in the control of cell proliferation and death (Vogelstein et al, 1988 ; Kinzler and Vogelstein, 1996; Shibata, 1996) . These malignancies are characterized by aneuploidy at the cytogenetic level and, at the molecular level, by allelic losses in an average of at least 25% of randomly chosen DNA sequences . The prototypic hereditary cancer syndrome of this pathway is familial adenomatous polyposis (FAP) (Kinzler and Vogelstein, 1996; Perucho, 1996) . The 'mutator pathway' has been recognized in a subset of sporadic gastric and colorectal, but not pancreatic, cancers (Ionov et al, 1993; Thibodeau et al, 1993; Strickler et al, 1994; Hahn et al, 1995; Konishi et al, 1996) and is a feature of cancers arising in hereditary non-polyposis colorectal cancer (HNPCC) (Lynch et al, 1993 ; Konishi et al, 1996) . These cancers have been defined as USM+ (ubiquitous somatic mutations positive), RER+ (replication error positive) or as being of the mutator phenotype. They have defective DNA mismatch repair genes (mutator genes) (Umar et al, 1994; Liu et al, 1995a) , causing the accumulation of hundreds of thousands of unrepaired mutations during cell replication cycles. Such a 'DNA phenotype', that is, the existence of widespread mutations throughout the genome, is easily detected by the analysis of simple repeat motifs of 1-4 bp (microsatellites), which are particularly prone to insertions or deletions (Liu et al, 1995b) . In addition, USM+ gastrointestinal cancers are usually euploid or near-diploid and rarely show chromosomal losses (Strickler et al, 1994; Kinzler and Vogelstein, 1996) . In these cancers, the impaired function of DNA repair genes also causes the mutational activation or inactivation of functional genes (Shibata, 1996) . In particular, the tumour growth factor-p type H receptor gene (TGF-PRII) is inactivated in almost all USM+ gastric and colonic cancers, which escape, in this way, the TGF-p-mediated growth control Myeroff et al, 1995; Parsons et al, 1995; Wang et al, 1995; Shibata, 1996) .
We analysed paraffin-embedded samples from 12 duodenal cancers for the genetic anomalies involved in the genesis and progression of malignancy of gastrointestinal cancers. These included (a) those characteristic of tumour suppressor pathogenesis -alterations of Ki-ras gene and p53 protein; loss of heterozygosity (LOH) at chromosomal arms 5q21, 17pl3, 18q21 and 3pl4, which include the loci of APC (adenomatous polyposis coli), p53, DCC (deleted in colon cancer) and FHIT tumour-suppressor genes respectively (Vogelstein et al, 1988; Kinzler and Vogelstein, 1996; Ohta et al, 1996) ; and (b) those characteristic of the USM+ cancers -microsatellite instability and truncating mutations in TGF-PRII receptor gene. In two cases, for which high-molecular-weight DNA from frozen samples was available, we could also characterize APC and p53 gene mutations. We report that sporadic cancers of duodenal non-ampullary origin may arise from either the tumour-suppressor or the mutator pathway, thus parallelling the molecular pathogenesis of gastric and colorectal cancers.
MATERIALS AND METHODS Patients and tumours
Twelve cancers of unequivocal duodenal origin were retrieved from the files of the Department of Pathology of Verona University, Italy. They were selected from cancers of patients who underwent pancreaticoduodenectomy in the period 1985-1997. Ampullary and all periampullary cancers for which unequivocal duodenal origin could not be established were excluded from the study. The patients included seven men and five women, whose clinicopathological characteristics are reported in Table 1 . All cancers but two (DC3 and DC5) presented as ulcerated masses. Staging was performed using the American Joint Committee on Cancer (AJCC) criteria for small intestinal malignancies (AJCC, 1992) (Table 1) . Two cancers were confined to the duodenal wall: DC2 involved the muscularis propria and DC6 the duodenal submucosa. Three were transmural cancers (DC3, DC4 and DC5), with infiltration of the periduodenal fat and pancreas. The average number of lymph nodes isolated from the surgical specimens was 16 (range 4-33), and nodal metastases were present in seven cancers. All patients had a negative personal and familial history for cancer, including FAR In all cases, cancer cell-rich areas and matched normal mucosa were isolated from formalin-fixed paraffin-embedded blocks, and DNA was extracted as described (Achille et al, 1995) . In cases DC1 and DC2, frozen samples were also available and were enriched to a neoplastic cellularity of more than 70% by cryostat dissection (Achille et al, 1996a) . In these two cases, highmolecular-weight DNA was prepared by standard methods from 80 6-jim cryostatic sections, the cell composition of the sample being ascertained every 20 sections, and normal DNA was obtained from frozen strips of normal duodenal mucosa of each patient.
Molecular analysis
All cases were studied for mutations of Ki-ras and TGF-PR1I genes, allelic losses at chromosomes 3p, 5q, 17p and 18q using polymerase chain reaction (PCR)-based methods, as well as for p53 protein nuclear accumulation using immunohistochemistry. Mutations of APC and p53 genes were only analysed in the two cases with available high-molecular-weight DNA from frozen tissues, because of the inadequacy of degraded DNA from paraffin-embedded tissues for such analyses.
Mutations of Ki-ras codon 12 were screened by mutantenriched PCR and characterized by allele-specific oligonucleotide hybridization (ASO), according to Hruban et al (1993) . Immunohistochemistry for p53 protein was performed on paraffin sections, using pAbl801 monoclonal antibody (Scarpa et al, 1993) . Truncating mutations of APC gene were searched using the APC protein truncation test (PTT) analysis of codons 654-1700, as previously described in detail (Achille et al, 1996b) . Mutations of the p53 gene were investigated using single-strand conformation polymorphism and direct DNA sequencing of PCR-amplified DNA fragments (Scarpa et al, 1993) .
Microsatellite instability was assessed through PCR amplification of four loci, including DlS158, DXS538, MAOB and APA3. LOH at specific chromosomal loci was examined by PCR amplification of ten microsatellites. These included D5S82 and D5S299 for chromosome 5q21; D17S513, D17S1176 and D17S559 for chromosome l7pl3; D18S65, D18S61 and D18S55 for chromosome 18q21; D3S1234 and D3S1300 for chromosome 3pl4. All appropriate primers for amplification of microsatellites were purchased from the MapPairs collection (Research Genetics, Huntsville, AL, USA). They were used at the annealing temperature indicated by the manufacturer when using high-quality DNA from frozen tissues and at 5°C lower when using DNA from paraffin-embedded tissues. The PCR reaction (10,l) and product detection for microsatellite instability and LOH studies were performed as previously described in detail for high-quality DNAs 762 A Achille et al , whereas LOH was characterized by loss of the bands representing one allele (Achille et al, 1996a ).
The TGF-ORII gene was analysed by PCR amplification of the 73-bp (nucleotides 665-737) which contains the mutational hotspot represented by a 10-bp polyadenine tract (codons 125-128) Myeroff et al, 1995; Parsons et al, 1995) . Genomic DNA (50 and 100 ng) was amplified in duplicate experiments using forward [y-32P]ATP 5'-end-labelled primer TAIO-Fl (5'-CTlITATTCTGGAAGATGCTGC-3') and reverse primer TA1O-RI (5'-GAAGAAAGTCTCACCAGG-3') (Lin et al, 1992) , kindly provided by Professor RA Weinberg (Whithead Institute, MIT, Cambridge, MA, USA).
RESULTS
The results of the molecular studies are summarized in Table 1 , and details of chromosomal allelic losses are given in Table 2 . We first analysed the two cancers for which high-quality DNA from frozen samples was available (DC1 and DC2). After testing the suitability for genetic analysis of the partly degraded DNA from formalinfixed paraffin-embedded samples, as processed at our institution, we extended the study to the additional ten cases of our series.
Molecular analysis of cancers DC1 and DC2
Cancer DCI showed mutations in APC, Ki-ras and p53 genes, together with allelic losses at chromosomal loci 5q21, 17pl3 and 3p14 (Figure 1 ). Chromosome 18q21 alleles were retained, and neither microsatellite instability nor insertions or deletions in the TGF-fRII gene were found.
Cancer DC2 showed instability at all four microsatellites used for detection of this anomaly (Figure 2) , and also in the majority of the microsatellites (eight of ten) used for LOH analyses.
Therefore, it was classified as a USM+ neoplasm. The TGF-PRII gene of this cancer had a 1-bp deletion in both alleles within the polyadenine tract. Such biallelic mutation predicts an inactive truncated receptor protein of 161 amino acids . This case had neither APC, nor Ki-ras or p53 mutations. The two microsatellites not showing instability, D3S 1300 and D18S55, were both informative and showed no allelic loss. The absence of allelic losses at the 17pl3 locus was demonstrated by Southem blot analysis of MspI-digested DNA hybridized to the pYNZ22 probe (American Type Culture Collection, Rockville, MD, USA) (data not shown).
Adequacy of paraffin-embedded samples and summary of molecular anomalies
We assessed the adequacy of formalin-fixed and paraffin-embedded tissue from our institution by testing the DNA extracted from paraffin blocks of cancers DC1 and DC2 for Ki-ras and TGF-,RII mutations, microsatellite instability and LOH at chromosomes 17p and 18q (Figure 3) . The results perfectly matched those obtained with DNA from frozen tissues. We then extended the study to the remaining ten cases, whose partly degraded DNA could be successfully tested for all the molecular anomalies analysed in cases DC1 and DC2, with the exception of APC and p53 gene mutations. However, the detection of p53 protein accumulation in cell nuclei by immunohistochemistry serves as a surrogate for p53 gene mutations in gastrointestinal cancers Achille et al, 1996b) .
In summary, Ki-ras codon 12 mutations were detected in 5 of the 12 cancers (42%). They were GGT to GAT in four instances and GGT to GCT in one. Abnormal accumulation of p53 protein was found in eight cancers (67%), all showing immunostaining in the vast majority of cancer cell nuclei. Six of these eight cases had a complete loss of p53 function, as suggested by the concomitant loss of the normal p53 allele on chromosome 17p. Allelic losses at chromosomes 3p, Sq, 17p and 18q were found in two of nine (22%), six of ten (60%), six of nine (67%) and three of ten (30%) informative cancers, respectively. Three of the 12 cancers (25%) British Journal of Cancer (1998) 77(5) MAOB (CT4-CA23-CA4) of paired normal (N) and tumour (T) DNAs. In this case, the instability is represented by allelic shifts extending the normal allele size by a variable number of base pairs ranging from 4 to more than 20. The polyadenine tract of the TGF-,BRII gene shows a 1-bp deletion of both alleles (T), compared with the wild type pattern (N). This experiment was conducted in duplicate, using 100 ng of genomic DNA on the left N and T lanes, and 50 ng on the right N and T lanes showed widespread microsatellite instability of the type seen in USM+ cancers. Two of these three cancers (DC2 and DC4) showed a l-bp deletion in the TGF-3RII gene, whereas all the other cases scored negative. The occurrence of chromosomal losses could not be assessed in every locus of the three USM+ cancers, because of the instability at the microsatellite loci tested (Table 2) . Finally, the adenomatous component of case DC1 was microdissected and tested for selected genetic anomalies, including Kiras mutations and LOH at 5q21, l7pl3 and 3pl4 chromosomal loci. The results confirmed that the Ki-ras mutation was already present at the adenoma stage, whereas 5q21 and 17pl3 LOH were confined to the cancer tissue. In addition, p53 immunohistochemistry showed that the p53 mutated protein was accumulated in more than 90% of cancer cell nuclei but not in adenoma cells.
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DISCUSSION
Our study demonstrates that sporadic duodenal non-ampullary cancers may arise through each of the two known molecular pathways recognized in gastric and colonic cancers. The majority of our cases showed frequent chromosomal changes and mutations of Ki-ras and p53 genes, while widespread subtle alterations due to mismatch repair deficiency occurred in a minority.
Nine of the cases in our series may be considered to be cancers with a 'tumour-suppressor' pathogenesis. They included one of the two cancers confined to the duodenal wall, two of the three transmural cancers and all but one cancer with nodal metastases. Ki-ras mutations occurred in five of these cases (55%), whereas all but the cancer confined to the duodenal submucosa (case DC6) showed p53 alterations (89%). The most frequent chromosomal losses were at Sq and 17p, found in six of these nine cases (67%) and in six of eight informative cases (75%) respectively. Ki-ras mutations were found in cancers at different stages, also including one cancer confined to the duodenal wall, whereas p53 and chromosome 17p and 18q alterations were only associated with transmural and metastasizing cancers. The small number of cases and the fact that most cancers were already metastasizing made it difficult to reconstruct the timing of the different molecular changes. However, some insight on their sequential occurrence could be gained by the separate study of the adenomatous and carcinomatous components of case DC1. In this case, the mutations of Ki-ras, and possibly of APC, occurred at the adenoma stage, whereas the p53 mutation occurred at the time of carcinomatous transformation. The carcinomatous phase was also characterized by the complete inactivation of APC and p53 functions, by the deletion of the chromosomal 5q21 and 17pl3 loci containing their respective normal alleles. This scenario parallels that of the common type sporadic colorectal cancer. Such similarity is further supported by the fact that duodenal non-ampullary cancer only occurs at high frequency in patients affected by FAP, in whom it is the leading cause of death after colorectal cancer (Achille et al, 1996b) . In this condition, it largely exceeds, in frequency, those originating from the structures of the papilla of Vater, and also shows frequent somatic mutations in the adenomatous polyposis coli (APC) gene, besides germline mutations (Achille et al, 1996b) .
Three cases in our series (25%) were considered to be typical USM+ tumours, showing widespread microsatellite instability, and two of them also had a truncating mutation of the TGFP-RII gene.
These cases included one moderately differentiated, one colloid and one poorly differentiated cancer, without evidence of Ki-ras or p53 mutations. Gastric and colorectal USM+ cancers differ from their USM-counterpart in that they frequently show poor differentiation or colloid features, a low representation of p53 mutations and a low frequency of lymph node metastasis (Lothe et al, 1993; Kim et al, 1994; Dos Santos et al, 1996; Shibata, 1996) . It is also interesting that the three USM+ cancers in our study showed no chromosomal losses at their few informative loci. This further illustrates the similarity between duodenal USM+ cancers and those observed in stomach and colon, which rarely show chromosomal losses Jen et al, 1994; Strickler et al, 1994; Shibata, 1996) , at variance with the high frequency of losses observed in USM-cancers. All three patients with USM+ duodenal cancers, including two with local disease and one with a metastasizing lesion, were long survivors with no evidence of disease. This is again reminiscent of colorectal and gastric USM+ cancers, which are usually diagnosed at a stage earlier than that of USMcommon cancers, and bear a good prognosis even in the presence of nodal metastases (Thibodeau et al, 1993; Kim et al, 1994; Dos Santos et al, 1996; Konishi et al, 1996) . The observation that patient DC11 was still alive more than 12 years from surgery, together with the possibility of testing USM status on DNA from paraffin-embedded material, should hopefully prompt researchers with available larger series to test the several reported patients with lymph node-positive duodenal cancers surviving for as long as 9 years (Rose et al, 1996; Sexe et al, 1996) .
We conclude that sporadic duodenal non-ampullary cancers share similar molecular pathogenetic pathways to those of gastric and colorectal cancers. The small number of cases available at our institution does not allow the assessment of the prognostic value of the molecular variables through a survival analysis. However, our preliminary findings, if confirmed in a larger series, would suggest that, at least, USM status may be used as a prognostic marker that is as useful for patients with duodenal cancers as for those with gastric and colorectal malignancies (Lothe et al, 1993; Thibodeau et al, 1993; Jen et al, 1994; Kim et al, 1994; Dos Santos et al, 1996; Konishi et al, 1996; Shibata, 1996) . ABBREVIATIONS APC, adenomatous polyposis coli gene; FAP, familial adenomatous polyposis; HNPCC, hereditary non-polyposis colorectal cancer; LOH, loss of heterozygosity; PCR, polymerase chain reaction; PTT, protein truncation test; RER, replication error; TGF-PRII, transforming growth factor beta type II receptor; USM, ubiquitous somatic mutations; USM+ and USM-, ubiquitous somatic mutations positive and negative respectively
